Abstract
Background
Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), but its use is hampered by secondary drug resistance. Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which is crucial for liver tumorigenesis. As yet, however, the mechanism underlying sorafenib resistance and the role of YAP therein is not fully understood and needs to be explored further.
Methods
Western blotting, flow cytometry and CCK-8 assays were used to assess the role of YAP in HCC sorafenib resistance. Next, qRT-PCR and Western blotting were performed to identify survivin as a YAP downstream effector, and rescue experiments were performed to confirm that YAP induces sorafenib resistance via survivin. Additionally, Western blotting, flow cytometry and in vivo xenograft models were used to evaluate the effect of verteporfin in combination with sorafenib on HCC.
Results
We found that sorafenib enhances YAP nuclear accumulation and activation, thereby promoting sorafenib resistance through inhibiting apoptosis in HCC cells. In addition, we found that survivin acts as a downstream mediator of YAP to resist sorafenib-induced apoptosis. Pharmacological inhibition of YAP by verteporfin increased the sensitivity of HCC cells to sorafenib and reversed sorafenib resistance. Moreover, verteporfin in combination with sorafenib significantly suppressed in vivo HCC tumor growth.
Conclusions
Our data indicate that YAP promotes sorafenib resistance through upregulation of survivin expression in HCC cells. Targeting YAP may be a therapeutic strategy to improve the antitumor effects of sorafenib in HCC.
Similar content being viewed by others
Data availability
The data and materials supporting the conclusion of this manuscript are included in the article.
Abbreviations
- HCC:
-
Hepatocellular carcinoma
- IHC:
-
Immunohistochemistry
- QRT-PCR:
-
quantitative real-time polymerase chain reaction
- siRNA:
-
Small interfering RNA
- YAP:
-
Yes-associated protein
References
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018)
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019)
J. Zucman-Rossi, A. Villanueva, J.C. Nault, J.M. Llovet, Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226-1239.e1224 (2015)
W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132 (2016)
J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, S.I.S. Group, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008)
M.S. Copur, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 2498; author reply 2498–2499 (2008)
J.F. Dufour, The evasive promise of antiangiogenic therapy. J. Hepatol. 51, 970–972 (2009)
M.A. Worns, P.R. Galle, HCC therapies–lessons learned. Nat. Rev. Gastroenterol. Hepatol. 11, 447–452 (2014)
C. Berasain, Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut 62, 1674–1675 (2013)
K.F. Harvey, X. Zhang, D.M. Thomas, The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013)
J. Huang, S. Wu, J. Barrera, K. Matthews, D. Pan, The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421–434 (2005)
F.X. Yu, B. Zhao, K.L. Guan, Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811–828 (2015)
B. Zhao, K. Tumaneng, K.L. Guan, The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 13, 877–883 (2011)
F. Zanconato, M. Cordenonsi, S. Piccolo, YAP/TAZ at the roots of cancer. Cancer Cell 29, 783–803 (2016)
M. Overholtzer, J. Zhang, G.A. Smolen, B. Muir, W. Li, D.C. Sgroi, C.X. Deng, J.S. Brugge, D.A. Haber, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U. S. A. 103, 12405–12410 (2006)
T. Zhang, J. Zhang, X. You, Q. Liu, Y. Du, Y. Gao, C. Shan, G. Kong, Y. Wang, X. Yang, L. Ye, X. Zhang, Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 56, 2051–2059 (2012)
J. Tao, D.F. Calvisi, S. Ranganathan, A. Cigliano, L. Zhou, S. Singh, L. Jiang, B. Fan, L. Terracciano, S. Armeanu-Ebinger, S. Ribback, F. Dombrowski, M. Evert, X. Chen, S.P.S. Monga, Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147, 690–701 (2014)
W. Kim, S.K. Khan, J. Gvozdenovic-Jeremic, Y. Kim, J. Dahlman, H. Kim, O. Park, T. Ishitani, E.H. Jho, B. Gao, Y. Yang, Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis. J. Clin. Invest. 127, 137–152 (2017)
S.M.E. Weiler, F. Pinna, T. Wolf, T. Lutz, A. Geldiyev, C. Sticht, M. Knaub, S. Thomann, M. Bissinger, S. Wan, S. Rossler, D. Becker, N. Gretz, H. Lang, F. Bergmann, V. Ustiyan, T.V. Kalin, S. Singer, J.S. Lee, J.U. Marquardt, P. Schirmacher, V.V. Kalinichenko, K. Breuhahn, Induction of chromosome instability by activation of yes-associated protein and forkhead box M1 in liver cancer. Gastroenterology 152, 2037-2051.e2022 (2017)
W.C. Yuan, B. Pepe-Mooney, G.G. Galli, M.T. Dill, H.T. Huang, M. Hao, Y. Wang, H. Liang, R.A. Calogero, F.D. Camargo, NUAK2 is a critical YAP target in liver cancer. Nat. Commun. 9, 4834 (2018)
S. Zhang, D. Zhou, Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr. Opin. Cell Biol. 61, 64–71 (2019)
L. Lin, A.J. Sabnis, E. Chan, V. Olivas, L. Cade, E. Pazarentzos, S. Asthana, D. Neel, J.J. Yan, X. Lu, L. Pham, M.M. Wang, N. Karachaliou, M.G. Cao, J.L. Manzano, J.L. Ramirez, J.M. Torres, F. Buttitta, C.M. Rudin, E.A. Collisson, A. Algazi, E. Robinson, I. Osman, E. Munoz-Couselo, J. Cortes, D.T. Frederick, Z.A. Cooper, M. McMahon, A. Marchetti, R. Rosell, K.T. Flaherty, J.A. Wargo, T.G. Bivona, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250–256 (2015)
T.Y. Zhou, L.H. Zhuang, Y. Hu, Y.L. Zhou, W.K. Lin, D.D. Wang, Z.Q. Wan, L.L. Chang, Y. Chen, M.D. Ying, Z.B. Chen, S. Ye, J.S. Lou, Q.J. He, H. Zhu, B. Yang, Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Sci. Rep. 6, 30483 (2016)
H. Xia, X. Dai, H. Yu, S. Zhou, Z. Fan, G. Wei, Q. Tang, Q. Gong, F. Bi, EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. Cell Death Dis. 9, 269 (2018)
A.M. Gomes, T.S. Pinto, C.J. da Costa Fernandes, R.A. da Silva, W.F. Zambuzzi, Wortmannin targeting phosphatidylinositol 3-kinase suppresses angiogenic factors in shear-stressed endothelial cells. J. Cell. Physiol. 235, 5256–5269 (2020)
F. Pitoia, F. Jerkovich, Selective use of sorafenib in the treatment of thyroid cancer. Drug Des. Devel. Ther. 10, 1119–1131 (2016)
R. Johnson, G. Halder, The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 13, 63–79 (2014)
D. Pan, The hippo signaling pathway in development and cancer. Dev. Cell 19, 491–505 (2010)
Z. Meng, T. Moroishi, K.L. Guan, Mechanisms of Hippo pathway regulation. Genes Dev. 30, 1–17 (2016)
D.D. Shao, W. Xue, E.B. Krall, A. Bhutkar, F. Piccioni, X. Wang, A.C. Schinzel, S. Sood, J. Rosenbluh, J.W. Kim, Y. Zwang, T.M. Roberts, D.E. Root, T. Jacks, W.C. Hahn, KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171–184 (2014)
A. Kapoor, W. Yao, H. Ying, S. Hua, A. Liewen, Q. Wang, Y. Zhong, C.J. Wu, A. Sadanandam, B. Hu, Q. Chang, G.C. Chu, R. Al-Khalil, S. Jiang, H. Xia, E. Fletcher-Sananikone, C. Lim, G.I. Horwitz, A. Viale, P. Pettazzoni, N. Sanchez, H. Wang, A. Protopopov, J. Zhang, T. Heffernan, R.L. Johnson, L. Chin, Y.A. Wang, G. Draetta, R.A. DePinho, Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185–197 (2014)
J. Rosenbluh, D. Nijhawan, A.G. Cox, X. Li, J.T. Neal, E.J. Schafer, T.I. Zack, X. Wang, A. Tsherniak, A.C. Schinzel, D.D. Shao, S.E. Schumacher, B.A. Weir, F. Vazquez, G.S. Cowley, D.E. Root, J.P. Mesirov, R. Beroukhim, C.J. Kuo, W. Goessling, W.C. Hahn, beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457–1473 (2012)
W. Zhang, Y. Gao, F. Li, X. Tong, Y. Ren, X. Han, S. Yao, F. Long, Z. Yang, H. Fan, L. Zhang, H. Ji, YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. Cancer Res. 75, 4450–4457 (2015)
K. Ma, Q. Xu, S. Wang, W. Zhang, M. Liu, S. Liang, H. Zhu, N. Xu, Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. Cancer Lett. 375, 84–91 (2016)
Y. Liu-Chittenden, B. Huang, J.S. Shim, Q. Chen, S.J. Lee, R.A. Anders, J.O. Liu, D. Pan, Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300–1305 (2012)
B. Zhai, X.Y. Sun, Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J. Hepatol. 5, 345–352 (2013)
C.A. Hall, R. Wang, J. Miao, E. Oliva, X. Shen, T. Wheeler, S.G. Hilsenbeck, S. Orsulic, S. Goode, Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70, 8517–8525 (2010)
J.M. Huang, I. Nagatomo, E. Suzuki, T. Mizuno, T. Kumagai, A. Berezov, H. Zhang, B. Karlan, M.I. Greene, Q. Wang, YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 32, 2220–2229 (2013)
A. Perra, M.A. Kowalik, E. Ghiso, G.M. Ledda-Columbano, L. Di Tommaso, M.M. Angioni, C. Raschioni, E. Testore, M. Roncalli, S. Giordano, A. Columbano, YAP activation is an early event and a potential therapeutic target in liver cancer development. J. Hepatol. 61, 1088–1096 (2014)
M.E. Garcia-Rendueles, J.C. Ricarte-Filho, B.R. Untch, I. Landa, J.A. Knauf, F. Voza, V.E. Smith, I. Ganly, B.S. Taylor, Y. Persaud, G. Oler, Y. Fang, S.C. Jhanwar, A. Viale, A. Heguy, K.H. Huberman, F. Giancotti, R. Ghossein, J.A. Fagin, NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discov. 5, 1178–1193 (2015)
E. Ciamporcero, H. Shen, S. Ramakrishnan, S. Yu Ku, S. Chintala, L. Shen, R. Adelaiye, K.M. Miles, C. Ullio, S. Pizzimenti, M. Daga, G. Azabdaftari, K. Attwood, C. Johnson, J. Zhang, G. Barrera, R. Pili, YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 35, 1541–1553 (2016)
T. Moroishi, C.G. Hansen, K.L. Guan, The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73–79 (2015)
N. Gronich, G. Rennert, Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat. Rev. Clin. Oncol. 10, 625–642 (2013)
Funding
This project was supported by the National Natural Science Foundation of China (No. 81874188) and the Science and Technology Project of Henan province of China (No. 202102310119).
Author information
Authors and Affiliations
Contributions
TS designed the study and prepared the manuscript; WM and HP performed most of the experiments; TS and LJ analyzed the data and competed the figures; QW revised the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
All experiments were performed in accordance with the standards of the ethics committee of the First Affiliated Hospital of Zhengzhou University.
Consent for publication
Not applicable.
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Supplemental Fig. 1
The protein levels of YAP were analyzed by western blotting assay in liver cancer cell lines and in a normal human hepatic cell line LO2 (PNG 39 kb) (PNG 24 kb)
Supplemental Fig. 2
Huh-7R and HepG2R were resistant to sorafenib induced apoptosis. (a, b) Huh-7R and HepG2R cells were exposed to the indicated doses of sorafenib for 24 h. Cells were collected for western blotting. (c, d) Proteins from the cytoplasm and nucleus were separated, and the localization of YAP were detected by western blotting. (e, f) The mRNA expressions of CTGF and CYR61 were analyzed by qRT-PCR. Results were presented as mean ± sem (n = 3) for each treatment (PNG 114 kb)
Supplemental Fig. 3
Knockdown YAP expression using shRNAs in Huh-7 and HepG2 cells. Huh-7 and HepG2 cells were transfected with shYAP. (a, b) The protein levels of YAP were analyzed with western blotting. (c, d) The mRNA levels of YAP were analyzed with RT-PCR (PNG 83 kb)
Supplemental Fig. 4
Sorafenib had no significant effect on YAP mRNA expression. (a-b) Huh-7 and HepG2 cells transfected with shYAP were treated with sorafenib for 24 h. The mRNA levels of YAP were analyzed with RT-PCR (PNG 39 kb)
Supplemental Fig. 5
YAP attenuated the cytotoxicity of sorafenib. (a, b) Huh-7 and HepG2 cells transfected with shRNA were treated with different concentration of sorafenib for 72 h. Cell viability was measured by CCK-8. (c) LO2 cells transfected with flag-YAP or vector were treated with different concentration of sorafenib for 72 h. Cell viability was measured by CCK-8 (PNG 35 kb)
Supplemental Fig. 6
YAP inhibitor verteporfin reversed sorafenib resistance. (a, b) Huh-7R and HepG2R cells were treated with sorafenib in combination with or without verteporfin for 24 hours. Cells were analyzed using western blotting. (c, d) Huh-7R and HepG2R cells were treated with different combinations of sorafenib and verteporfin for 72 h. Cell viability was measured by CCK-8. (e, f) Huh-7R and HepG2R cells were treated with different combinations of sorafenib and verteporfin. Cells viability was analyzed by colony formation assay. Columns were the average of three independent experiments. (g) Huh-7R and HepG2R cells were treated with different combinations of sorafenib and verteporfin for 48 h. Cells were analyzed by flow cytometry. Columns were the average of three independent experiments. Results were presented as mean ± sem (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 (PNG 629 kb)
Rights and permissions
About this article
Cite this article
Sun, T., Mao, W., Peng, H. et al. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cell Oncol. 44, 689–699 (2021). https://doi.org/10.1007/s13402-021-00595-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-021-00595-z